Clinical trials for Breast cancer

200 currently recruiting clinical trials

Phase 2 Breast cancer #NCT04985266
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery Chemotherapy Hormone therapy
Excluded previous treatments at localized stage
Targeted therapy
18 recruiting sites
Fiducie de la Fondation Royal Marsden NHS
Phase 2 Breast cancer #NCT07193394 #2024-519624-24-00
Required HER2 statuses
HER2 Negative
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
Other mutation
Required number of previous lines of therapy for current stage of disease
2 3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy Hormone therapy
1 recruiting site
Institut Curie
Phase 2 Breast cancer #NCT04965766 #2023-505923-30-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required previous treatments at advanced or metastatic stage
Chemotherapy Targeted therapy Hormone therapy
10 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 2 Breast cancer #NCT06330064 #2023-509632-26-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
2 3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
10 recruiting sites
Daiichi Sankyo
Phase 2 Breast cancer #NCT06330064 #2023-509632-26-00
Required HER2 statuses
HER2 Low
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
2 3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
10 recruiting sites
Daiichi Sankyo
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06653777 #2024-512729-10-00
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
FGFR
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
UNICANCER
Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer #NCT05732831 #2022-502645-99-00
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
MTAP
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Tango Therapeutics
Phase 2 Breast cancer #NCT05297617 #2024-514480-26-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery Hormone therapy
Excluded previous treatments at localized stage
Chemotherapy
37 recruiting sites
UNICANCER
Phase 2 Breast cancer #NCT06078384 #2023-504620-26-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Immunotherapy
24 recruiting sites
UNICANCER
Phase 2 Breast cancer #NCT06450314 #2023-509811-98-00
Required HER2 statuses
HER2 Positive
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
UNICANCER